Program
Targeted CEA CAR-T
Its studies are mostly in Lung Neoplasms, led by Chongqing Precision Biotech.
Furthest: phase 1, since Dec 12, 20244 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Precision Biotech | 44 open or running | phase 1since Dec 12, 2024 | Dec 12, 2024 | Dec 31, 2026phase 1 · NCT06768151 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2024First study: phase 1 study in Advanced Lung CancerFirst studyNCT06768151 · 48 planned · China
- Mar 24, 2025Phase 1 study in Advanced Lung CancerNCT06903117 · 60 planned · China
- Apr 11, 2025Phase 1 study in Advanced Lung CancerNCT06945523 · 60 planned · China
- May 16, 2025Phase 1 study in Advanced Lung CancerNCT06992583 · 60 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Advanced Lung CancerNCT06768151
- Dec 31, 2027Primary completion: phase 1 study in Advanced Lung CancerNCT06945523
- Dec 31, 2027Primary completion: phase 1 study in Advanced Lung CancerNCT06903117
- Feb 29, 2028Primary completion: phase 1 study in Advanced Lung CancerNCT06992583
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06992583Advanced Lung Cancer · China | 1 | Recruiting | Feb 29, 2028 | 60 |
| NCT06945523Advanced Lung Cancer · China | 1 | Recruiting | Dec 31, 2027 | 60 |
| NCT06903117Advanced Lung Cancer · China | 1 | Recruiting | Dec 31, 2027 | 60 |
| NCT06768151Advanced Lung Cancer · China | 1 | Recruiting | Dec 31, 2026 | 48 |
How it is read
Names in the registry
- “Targeted CEA CAR-T”, 8 entries
Conditions, from the studies’ own filings
- Lung Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.